Main content

Virtual reality training

VIRTUES – Virtual Reality Training for Upper Extremity after Stroke


VIRTUES is a collaboration between five rehabilitation institutions in Norway, Denmark and Belgium and the KU Leuven, Belgium, coordinated by the University of Bergen, Norway. We want to examine whether Virtual reality training (VR) is more effective in improving arm motor function in the sub-acute phase after stroke than conventional training. The implementation of VR rehabilitation from therapists’ and patients’ points of view and cost-effectiveness will also be evaluated.

In this study the potential of a VR training system, the YouGrabber, will be compared to standard rehabilitation and assessed with regard to:


       Arm motor function      Dexterity      Patient satisfaction      Therapist satisfaction


              Independence in activities of daily living           Cost-effectiveness

European Congress on Neurorehabilitation and Neural Repair
Congress logo and VIRTES title

Results from the VIRTUES study

Results from the VIRTUES study will be presented at a focused symposium at the 2nd Congress for Neurorehabilitation and Neural Repair 22-24 May 2017 in Maastricht, the Netherlands

New publication from VIRTUES trial
Air plane game

Is Virtual reality training more intensive than conventional training?

Results from this study indicate that patients with severely impaired upper limb motor function spent more time actively in VR training (VR) than in conventional training (CT).

Follow up
sign with the word follow up

The last follow up conducted today

The last follow up patient has been tested today at Hammel Neurocenter. With the last follow up data collection is concluded and the analyses can start. Therapists report that the follow up examininations 3 months after the intervention were a good experience for most patients.

Recruitment completed
traffic sign 120

VIRTUES trial patient recruitment completed

A new milestone reached: 120 patients have been included


Two-thirds recruited

Recruitment has reached a new stage, 82 of the targeted 120 patients have been included.